Skip to content
DeepViews

Merck & Co., Inc. (MRK) — Analysis Summary

Merck & Co., Inc. (MRK) has a market cap of $376.37B with year-over-year revenue growth of +1.3%. Net margin stands at 28.1%. The stock trades at a P/E ratio of 118.6.

Key Takeaways

  • Revenue changed +1.3% year-over-year
  • Net margin of 28.1%
  • P/E ratio of 118.6

Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, MRK posted revenue growth of +1.3% and trades at a P/E of 118.6.

[XNYS]

Merck & Co., Inc. (MRK)

$152.55

UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR

Market Cap
$376.37B
Enterprise Value
$423.13B
P/E Ratio
118.6
Div Yield
2.23%
EV/EBITDA
38.8
Company Profile
About
About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. In cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 53% of the company's 2025 sales were generated from US human health (pharmaceuticals and vaccines).

Sector

PHARMACEUTICAL PREPARATIONS

Employees

75,000

Headquarters

RAHWAY, NJ

Exchange

XNYS

Website
Source: Polygon.io
Score
Competitive Moat
Competitive Moat
43
Narrow Moat

Systematic competitive advantage assessment based on 4yr data

This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.

Market Signals
Valuation
Earnings
Insider Activity
Insider Filing Activity

First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.

Loading SEC insider filing activity...
Superinvestors
Financial Health
Financial Health

Capital Structure

Total Equity$41.98B
Total Debt$53.91B
Debt-to-Equity1.28
Cash & Equivalents$6849.00M

Cash Flow

Operating Cash Flow$19.97B
Free Cash Flow$16.06B
FCF Margin24.13%
P/FCF Ratio23.43
Source: Polygon.io · SEC EDGAR
Dividends
Dividends

Annual Dividend/Share

$3.40

Dividend Yield

2.23%

Quarterly
Last Ex-Date: 2026-09-15

Dividend History

2026-09-15
CD$0.8500
2026-06-15
CD$0.8500
2026-03-16
CD$0.8500
2025-12-15
CD$0.8500
Source: Polygon.io
Recent News
Recent News

Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.